BR9908726A - Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto - Google Patents
Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um compostoInfo
- Publication number
- BR9908726A BR9908726A BR9908726-0A BR9908726A BR9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A BR 9908726 A BR9908726 A BR 9908726A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- processes
- diseases
- diabetes
- type
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 abstract 1
- 108091006442 Mitochondrial phosphate transporters Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrodes Of Semiconductors (AREA)
- Enzymes And Modification Thereof (AREA)
- Bipolar Transistors (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Control Of El Displays (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK34498 | 1998-03-12 | ||
| DK48098 | 1998-04-03 | ||
| DKPA199800938 | 1998-07-15 | ||
| DKPA199801385 | 1998-10-28 | ||
| DKPA199801612 | 1998-12-07 | ||
| PCT/DK1999/000121 WO1999046267A1 (en) | 1998-03-12 | 1999-03-11 | Modulators of protein tyrosine phosphatases (ptpases) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9908726A true BR9908726A (pt) | 2000-11-21 |
Family
ID=27512769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9908726-0A BR9908726A (pt) | 1998-03-12 | 1999-03-11 | Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1080095B1 (enExample) |
| JP (1) | JP2002506072A (enExample) |
| KR (1) | KR20010041814A (enExample) |
| CN (1) | CN1300291A (enExample) |
| AT (1) | ATE308546T1 (enExample) |
| AU (1) | AU2713599A (enExample) |
| BR (1) | BR9908726A (enExample) |
| CA (1) | CA2323493A1 (enExample) |
| DE (1) | DE69928100D1 (enExample) |
| HU (1) | HUP0104984A3 (enExample) |
| IL (1) | IL138319A0 (enExample) |
| NO (1) | NO20004527L (enExample) |
| PL (1) | PL342816A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| EP1510207A4 (en) * | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | THERAPEUTIC MEDICAMENT AGAINST DIABETES |
| AU2003242127A1 (en) * | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
| JP4743382B2 (ja) | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| US20060122243A1 (en) | 2002-06-06 | 2006-06-08 | Susumu Muto | Antiallergic |
| DK1753512T3 (da) * | 2004-05-28 | 2008-11-17 | 4Sc Ag | Tetrahydropyridothiophener |
| ATE397000T1 (de) * | 2004-06-04 | 2008-06-15 | Nycomed Gmbh | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs |
| WO2005120642A2 (en) * | 2004-06-11 | 2005-12-22 | Altana Pharma Ag | Tetrahydropyridothiophenes for treating hyperproliferative disorders |
| NZ587549A (en) * | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| AU2006212224A1 (en) * | 2005-02-09 | 2006-08-17 | 4Sc Ag | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| CA2596501A1 (en) * | 2005-02-11 | 2006-08-17 | Altana Pharma Ag | Tetrahydropyridothiophenes as antripoliferative agents for the treatment of cancer |
| CA2621830C (en) * | 2005-09-15 | 2013-12-03 | F. Hoffmann-La Roche Ag | 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| MX388468B (es) | 2009-12-04 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Compuestos multicíclicos y métodos de uso de los mismos. |
| CN102382076B (zh) * | 2010-09-03 | 2016-08-17 | 中国医学科学院药物研究所 | 芳酮和芳酰胺类化合物及其制法和药物用途 |
| CN102838625B (zh) * | 2011-06-22 | 2015-04-15 | 中国科学院上海药物研究所 | 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
| JP6409004B2 (ja) * | 2013-01-28 | 2018-10-17 | ハー・ルンドベック・アクチエゼルスカベット | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 |
| CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
| CN106866523A (zh) * | 2015-03-12 | 2017-06-20 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104725306A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
| CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
| CN104829629B (zh) * | 2015-03-26 | 2017-03-15 | 天津药物研究院有限公司 | 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途 |
| WO2018023070A1 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
| MY199446A (en) | 2016-07-29 | 2023-10-28 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| AU2018220509B2 (en) | 2017-02-16 | 2022-04-28 | Sumitomo Pharma America, Inc. | Methods of treating schizophrenia |
| KR20200036008A (ko) | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로만 화합물 및 이의 용도 |
| MY208150A (en) | 2018-02-16 | 2025-04-18 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| WO2020233645A1 (zh) | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| WO2021211191A1 (en) * | 2020-04-14 | 2021-10-21 | Purdue Research Foundation | Novel lymphoid-specific tyrosine phosphatase (lyp) inhibitors |
| JP7781768B2 (ja) | 2020-04-14 | 2025-12-08 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | 神経学的および精神障害の治療方法 |
-
1999
- 1999-03-11 CN CN99806016A patent/CN1300291A/zh active Pending
- 1999-03-11 BR BR9908726-0A patent/BR9908726A/pt not_active IP Right Cessation
- 1999-03-11 KR KR1020007010093A patent/KR20010041814A/ko not_active Withdrawn
- 1999-03-11 DE DE69928100T patent/DE69928100D1/de not_active Expired - Lifetime
- 1999-03-11 CA CA002323493A patent/CA2323493A1/en not_active Abandoned
- 1999-03-11 IL IL13831999A patent/IL138319A0/xx unknown
- 1999-03-11 PL PL99342816A patent/PL342816A1/xx not_active Application Discontinuation
- 1999-03-11 AT AT99907332T patent/ATE308546T1/de not_active IP Right Cessation
- 1999-03-11 JP JP2000535645A patent/JP2002506072A/ja not_active Withdrawn
- 1999-03-11 EP EP99907332A patent/EP1080095B1/en not_active Expired - Lifetime
- 1999-03-11 AU AU27135/99A patent/AU2713599A/en not_active Abandoned
- 1999-03-11 HU HU0104984A patent/HUP0104984A3/hu unknown
-
2000
- 2000-09-11 NO NO20004527A patent/NO20004527L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1080095A1 (en) | 2001-03-07 |
| PL342816A1 (en) | 2001-07-02 |
| CN1300291A (zh) | 2001-06-20 |
| NO20004527D0 (no) | 2000-09-11 |
| IL138319A0 (en) | 2001-10-31 |
| AU2713599A (en) | 1999-09-27 |
| ATE308546T1 (de) | 2005-11-15 |
| CA2323493A1 (en) | 1999-09-16 |
| KR20010041814A (ko) | 2001-05-25 |
| DE69928100D1 (de) | 2005-12-08 |
| JP2002506072A (ja) | 2002-02-26 |
| EP1080095B1 (en) | 2005-11-02 |
| NO20004527L (no) | 2000-11-07 |
| HUP0104984A2 (hu) | 2002-04-29 |
| HUP0104984A3 (en) | 2003-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9908726A (pt) | Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto | |
| BRPI0309689A2 (pt) | formulação de uma mistura de flavonóides de anel-b-livre e flavanos como agente terapêutico. | |
| BR9809006A (pt) | Composição, processo para produzir a mesma, processos de liberação de uma proteìna a uma célula de um indivìduo, de liberação de uma proteìna, polipeptìdeo, peptìdeo e/ou medicamentos não proteináceos/composto terapêutico a uma célula de um indivìduo, para induzir uma resposta imune em um indivìduo, para liberar uma molécula de ácido nucleico a uma célula de um indivìduo,e, composição farmacêutica | |
| BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
| BRPI0414489A (pt) | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sague quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina | |
| BR0212512A (pt) | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta | |
| BRPI0409447A (pt) | ácidos fenilalcanóicos substituìdos | |
| BRPI0411982A (pt) | glicano de aperfeiçoamento de terapia | |
| BR0314577A (pt) | Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| Olianas et al. | Inhibition of TNF-α-induced neuronal apoptosis by antidepressants acting through the lysophosphatidic acid receptor LPA1 | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| BRPI0510664B8 (pt) | derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios | |
| Kumar et al. | 1, 2-benzenedicarboxylic acid, bis (2-methyl propyl) ester isolated from Onosma bracteata Wall. inhibits MG-63 cells proliferation via Akt-p53-cyclin pathway | |
| Gao et al. | Liquiritin, a flavone compound from licorice, inhibits IL-1β-induced inflammatory responses in SW982 human synovial cells | |
| Pelc et al. | Incorporation of labelled thymidine in the seminal vesicle of the mouse | |
| Aleem et al. | History and Traditional uses of Tiryaq (Theriac): An important formulation in Unani medicine | |
| Zaheer et al. | GMF-knockout mice are unable to induce brain-derived neurotrophic factor after exercise | |
| BRPI0414148A (pt) | derivados de imidazol | |
| KR101920152B1 (ko) | 면역증진 효과가 있는 녹용약침 및 이의 조제방법 | |
| Sabi et al. | Anti-inflammatory and anti-hyperuricemic effect of Ficus benghalensis bark extract in raw 246.7 cell line | |
| BRPI0606388A2 (pt) | composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto | |
| Hassan et al. | A vitamin DC/D ring-derived compound with cytotoxicity | |
| AU734887B2 (en) | Therapeutic agent and treatment for canine intractable dermatitis | |
| CN108245500A (zh) | 王浆酸在制备治疗腺苷脱氨酶活性升高的疾病药中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |